Navigation Links
CRESTOR(R) Reduced Risk of Blood Clots in the Veins
Date:3/29/2009

slipidemia. CRESTOR is also indicated as an adjunct to diet to slow the progression of atherosclerosis as part of a treatment strategy to lower Total-C and LDL-C to target levels. CRESTOR is not approved to prevent cardiovascular morbidity and mortality.

CRESTOR is contraindicated in patients with a known hypersensitivity to any component of this product, in patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels, in women who are pregnant or may become pregnant, and in nursing mothers.

Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with HMG-CoA reductase inhibitors, including CRESTOR. These risks can occur at any dose level, but are increased at the highest dose (40 mg).

CRESTOR should be prescribed with caution in patients with predisposing factors for myopathy (eg, age Greater Than or Equal To 65 years, inadequately treated hypothyroidism, renal impairment). The risk of myopathy during treatment with CRESTOR may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine, or lopinavir/ritonavir.

Therapy with CRESTOR should be discontinued if markedly elevated CK levels occur or myopathy is diagnosed or suspected. All patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. It is recommended that liver enzyme tests be performed before and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (e.g., semiannually) thereafter. Should an increase in ALT or AST of >3 times ULN persist, reduction of dose or withdrawal of CRESTOR is recommended. CRESTOR should be used with caution in patients who consume substantial quantities of alcohol.

CRESTOR 40 mg shoul
'/>"/>

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
2. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
3. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
4. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
5. Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study
6. Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome
7. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
8. Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation
9. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
10. ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments
11. Spherics, Inc. Announces Reduced Cognitive Impairment of Novel Extended Release Topiramate (SRx-502) as Compared to Topamax(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... YORK , Oct. 30, 2014  The number ... States is growing steadily, thanks to drug ... as a result of the economic downturn, retail clinic ... a year of opportunities, as the number of retail ... researcher,s report, Retail Clinics Market Overview and 2014 ...
(Date:10/30/2014)... Oct. 30, 2014 Molecular Profiles Ltd., a ... ) and Maryland -based Xceleron have ... efficiency during clinical development that will be launched at ... week. This partnership extends Molecular Profiles, new ... launched earlier this month. The company also has complementary ...
(Date:10/30/2014)... Oct. 30, 2014  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced an upcoming ... drug candidate, aldoxorubicin.  The presentation, titled, "Drug Conjugates ... be given by Sant P. Chawla , ... and principal investigator of the Company,s ongoing global, ...
Breaking Medicine Technology:Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4
... April 26 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced ... calls focused on the drugs in Isis, development pipeline.  The second call of ... Wednesday, April 28, 2010 at 12:00 p.m. ET .  This ... , , ...
... , TITUSVILLE, N.J. , April 26 The Court ... Pediatrics, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., to overturn a 2009 decision ... for CONCERTA (methylphenidate HCl) Extended-Release Tablets CII is invalid and not infringed ... , In ...
Cached Medicine Technology:Isis Pharmaceuticals to Discuss Its Metabolic Franchise in a Conference Call on Wednesday, April 28 2Isis Pharmaceuticals to Discuss Its Metabolic Franchise in a Conference Call on Wednesday, April 28 3CONCERTA(R) Patent Appeal Denied 2CONCERTA(R) Patent Appeal Denied 3
(Date:10/30/2014)... October 30, 2014 Paramount Rx, a ... is increasing efforts to help people save money through ... to increase for prescription drugs in the new health ... and resources to bridge the relationship between consumers, businesses ... the biggest challenges people face today with medical costs ...
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, Oct. 29, ... prostate cancer who also have certain heart problems may increase ... study suggests. , , The therapy in question is called androgen ... levels of male hormones to prevent the growth of cancer ... this hormone therapy was linked to triple the risk of ...
(Date:10/30/2014)... Dennis Thompson HealthDay Reporter ... in Liberia -- one of three West African nations ravaged ... officials said Wednesday. Dr. Bruce Aylward, WHO,s assistant director ... burials in Liberia and no increase in laboratory-confirmed cases. He ... tame the epidemic may be making some progress, The ...
(Date:10/30/2014)... IL (PRWEB) October 30, 2014 Dr. Joseph ... a new website for his practices; OB GYN in ... IL . This website contains important information about each ... as well as downloadable patient forms in English and Spanish. ... and the service pages on the website provide Dr. Furlin’s ...
(Date:10/30/2014)... Francisco, California (PRWEB) October 30, 2014 ... billion by 2020, according to a new study by ... coupled with surging demand for sugar and fat free ... to augment the demand for prebiotics over the forecast ... http://www.grandviewresearch.com/industry-analysis/prebiotics-market , Food & beverage was the ...
Breaking Medicine News(10 mins):Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 2Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 4Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 5
... that men who have undergone vasectomy may be at ... study was published in Cognitive and Behavioural Neurology. ... of this, 25 developed a dementia called primary progressive ... the chief scientist of this study Sandra Weintraub, this ...
... have multiple sclerosis (MS) for 10 years and have few of ... “benign MS” and that their symptoms will likely not ever occur ... study shows that unfortunately this may not be correct. ... of those whose MS was benign at 10 years, according to ...
... test that can distinguish between a pair of nearly ... treatment. ,Their report is published this week ... the National Academy of Sciences. ,"This simple ... quickly implemented in the clinic to benefit patients by ...
... appreciable decline in the number of women dying at childbirth ... Gautemala and Morocco that have managed to arrest this trend. ... of maternal deaths per 100,000 live births, was 301 in ... 70,000 women die every year in India but UNICEF says ...
... An anti-smoking campaign in Colorado that involves door-to-door ... of thousands of dollars and "is raising questions ... cessation efforts among minorities, the Denver Rocky Mountain ... approved a tobacco tax increase, which so far ...
... a national study, patients being treated for a ... Shore University Hospital// (NSUH) and Long Island Jewish ... arsenic compound, coupled with standard chemotherapy treatments, significantly ... newly-diagnosed acute promyelocytic leukemia, or APL, and participated ...
Cached Medicine News:Health News:A New Two-gene Test to Discern Similar Gastrointestinal Cancers 2Health News:India Lags Far Behind in Controlling Maternal Deaths 2Health News:Arsenic Compound Effective in Treating Rare Leukemia 2Health News:Arsenic Compound Effective in Treating Rare Leukemia 3
... to Z Drug Facts produced by ... on thousands of medications. It provides ... effect, drug interactions, patient information and ... reference for physicians, students, residents, pharmacists, ...
Very concise book answering the question: "I've got a diagnosis, which drugs do I use?". All 15 chapters written by highly skilled US specialists...
... with Integrated Calculators, based on Davis's Drug ... advance in drug reference. DDGNIC contains the ... Guide (9th Edition) and has integrated calculation ... product merges many of the advantages of ...
Allows health professionals to answer consumers' questions regarding safety issues concerning possible drug-herb and drug-food interactions....
Medicine Products: